Scribd Logo
Cargar

¡Te damos la bienvenida a Scribd!

  • Study On The Small Molecule Receptor Tyrosine Kinase Inhibitor (SMRTKI) Dacomitinib in The Context of Breast Cancer Treatment

    Cargado por

    lilebtehalz
    11 vistas1 página
    Potential cancer theray in conjugation with other chemotherapeutics.This is a valuable paper as the drug dacomitinib has not yet been extensively researched and has not been documented for breast cancer, although there is a fair level of investigation of the drug in terms of other forms of cancer such as lung cancer and other cancer types which may be HER-receptor overexpressing in nature.

    Título original

    Study on the small molecule receptor tyrosine kinase inhibitor (SMRTKI) Dacomitinib in the context of breast cancer treatment

    Derechos de autor

    © © All Rights Reserved

    Formatos disponibles

    DOCX, PDF, TXT o lea en línea desde Scribd

    ¿Le pareció útil este documento?

    ¿Este contenido es inapropiado?

    Denunciar este documento
    Potential cancer theray in conjugation with other chemotherapeutics.This is a valuable paper as the drug dacomitinib has not yet been extensively researched and has not been documented for breast cancer, although there is a fair level of investigation of the drug in terms of other forms of cancer such as lung cancer and other cancer types which may be HER-receptor overexpressing in nature.

    Copyright:

    © All Rights Reserved
    Descargue como DOCX, PDF, TXT o lea en línea desde Scribd
    Marcar por contenido inapropiado
    11 vistas1 página

    Study On The Small Molecule Receptor Tyrosine Kinase Inhibitor (SMRTKI) Dacomitinib in The Context of Breast Cancer Treatment

    Cargado por

    lilebtehalz
    Potential cancer theray in conjugation with other chemotherapeutics.This is a valuable paper as the drug dacomitinib has not yet been extensively researched and has not been documented for breast cancer, although there is a fair level of investigation of the drug in terms of other forms of cancer such as lung cancer and other cancer types which may be HER-receptor overexpressing in nature.

    Copyright:

    © All Rights Reserved
    Descargue como DOCX, PDF, TXT o lea en línea desde Scribd
    Marcar por contenido inapropiado
    de 1

    Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid

    tumours- paper summary


    Abstract:
    Purpose
    Dacomitinib is a potent, orally available, irreversible inhibitor of tyrosine kinase human epidermal growth factor
    receptors HER1, HER2 and HER4.
    This first-in-human study investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of
    dacomitinib in patients with advanced solid malignancies, seven of whom comprised breast cancer as their primary
    tumour type.

    También podría gustarte